No­var­tis wins an­oth­er biosim­i­lar round with an OK for its Rit­ux­an copy­cat

No­var­tis just racked up its fourth new biosim­i­lar ap­proval in Eu­rope, this time gain­ing a thumbs up for its knock­off of Roche megablock­buster Rit­ux­an.

The EC gave the phar­ma gi­ant’s gener­ics unit San­doz a green light to sell Rixathon as a cheap­er al­ter­na­tive to its brand­ed ri­val at Roche. And it marks Roche’s sec­ond biosim­i­lar com­peti­tor, fol­low­ing Cell­tri­on’s win for Trux­i­ma, flagged through ear­li­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.